GlassScriptPhysician profile
Melissa Chamberlain
NPI 1609907914
$1,573.61
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $392 · 2023: $590 · 2024: $43.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.06 | 2021-2023 | Ofev |
| Novo Nordisk INC | $157.80 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $151.10 | 2021-2023 | Farxiga, Breztri |
| Dexcom, INC. | $135.86 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $132.54 | 2021-2023 | Jardiance |
| Abbott Laboratories | $125.00 | 2023 | Jeti |
| Takeda Pharmaceuticals U.S.A., INC. | $124.93 | 2021 | |
| Glaxosmithkline, LLC. | $93.19 | 2021-2024 | Shingrix, Bexsero, Arexvy |
| Novartis Pharmaceuticals Corporation | $72.57 | 2021-2023 | |
| Amgen INC. | $70.95 | 2021-2023 | Repatha |
| Abbvie INC. | $67.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.55 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $52.43 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.64 | 2021-2022 | |
| Astellas Pharma US INC | $19.08 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2022 | |
| Vivus LLC | $13.76 | 2021 | |
| Sanofi Pasteur INC. | $13.63 | 2021 | |
| Corium, LLC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.